Investor Presentaiton
FORWARD LOOKING STATEMENTS
alimera
This slide presentation and any discussion it accompanies may include "forward-looking statements," within the meaning of the
Private Securities Litigation Reform Act of 1995, regarding, among other things, Alimera's belief, expectation, or anticipation that:
Alimera's revenue will accelerate in 2024 and beyond; Alimera will continue to grow organically from its existing customer base;
Alimera will continue to expand access to ILUVIEN and YUTIQ in new markets and Alimera's clinical trials will demonstrate the results
that Alimera expects.
These forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors
that could delay, divert or change any of them, and could cause actual results to differ materially from those projected in its forward-
looking statements. Meaningful factors that could cause actual results to differ include (a) a slowdown or reduction in sales due to a
reduction in end user demand, unanticipated competition, regulatory issues, unexpected governmental actions or a delay in the
approval or commercialization of ILUVIEN for the treatment of non-infectious uveitis affecting the posterior segment in Europe, (b)
the NEW DAY Study may not produce the desired results and (c) other factors discussed in the "Risk Factors” and “Management's
Discussion and Analysis of Financial Condition and Results of Operations" sections of Alimera's Annual Report on Form 10-K for the
year ended December 31, 2022 and its most recent Quarterly Report on Form 10-Q, which are on file with the SEC and available at its
website.
In addition to the risks described above and in Alimera's reports and other filings with the SEC, other unknown or unpredictable
factors also could affect Alimera's results. There can be no assurance that the actual results or developments anticipated by Alimera
will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Alimera. Therefore, no
assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. All forward-
looking statements in this presentation and any discussion it accompanies are expressly qualified by the cautionary statements
contained or referred to herein. Alimera cautions investors not to rely too heavily on the forward-looking statements Alimera makes or
that are made on its behalf. These forward-looking statements speak only as of the date of this presentation (unless another date is
indicated). Alimera undertakes no obligation, and specifically declines any obligation, to publicly update or revise any such forward-
looking statements, whether as a result of new information, future events or otherwise.
Nasdaq: ALIM
2View entire presentation